Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

in the third quarter of 2008 from this study.

The CEA study is designed to evaluate the efficacy of VIA-2291 in the vessel wall, and has the unique advantage of providing access to atherosclerotic tissue for direct evaluation of VIA-2291's effect on inflammation, through a panel of assays and histological examinations.

Acute Coronary Syndrome (ACS) Study

The ACS study has enrolled more than two-thirds of the targeted 200 patients for this trial and top-line data results are anticipated to be released shortly after the release of data from the CEA trial. This study is designed to establish dose and safety data in patients with acute coronary syndrome (ACS) who have experienced a recent heart attack, and includes measures of leukotrienes, biomarkers of inflammation as well as medical imaging of the coronary vessel wall to evaluate impact on plaque characteristics.

About VIA-2291

VIA-2291 is a selective and reversible inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). Potentially a complement to current standard of care therapies that treat risk factors, such as statins, antiplatelet and blood pressure medications, VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiovascular event, but eventually could be beneficial to the broader 15.8 million patients in the U.S. who have coronary artery disease. VIA has exclusive worldwide rights to develop and commercialize VIA-2291. Based upon prior trials of VIA-2291 in more than 1,100 patients, VIA believes that VIA-2291 will be safe and well tolerated in doses currently being administered in the ongoing clinical trials.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovas
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EVANSVILLE, Ind. , Sept. 16, 2014   ... builder of custom, automated assembly and test systems, recently ... for a leading medical device manufacturer. The Evana solution ... improve quality and ergonomics, as well as reduce labor. ... are automatically fed to Evana,s robotic assembly cell. The ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... 16, 2014  Synereca Pharmaceutics, Inc. (SPI), ... active drugs that restore or increase the ... $1.4 million convertible debt financing. Accele Venture ... accelerator Accele Biopharma, Inc., led the financing ... recognized private not-for-profit corporation focused on growing ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... Council (NPC) today welcomed global specialty biopharmaceutical company Shire ... senior vice president, specialty pharma R&D, will serve as ... "The last few years have brought change ... important questions unresolved.  For the pharmaceutical industry, how ...
... Medical, Inc., a Minnesota-based medical device company, has announced that ... eripheral F acilitated A ntegrade S teering ... O cclusions (PFAST-CTOs) study.  The company received approval from ... US based IDE for the peripheral devices and is now ...
Cached Medicine Technology:National Pharmaceutical Council Welcomes Shire as Its Newest Member 2BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study 2
(Date:9/16/2014)... An experienced review website, Top10BestSEOHosting.com, has recently ... Bluehost and HostGator.com are among the best hosting ... high quality web hosting (including VPS and cloud ... now. , BlueHost ( http://www.bluehost.com/track/seohosts ) has ... a reliable and long-standing force in the world ...
(Date:9/16/2014)... The second federal bellwether trial involving ... subsidiary Ethicon concluded with the jury in the case ... her $3.27 million in damages, according to a September ... found Ethicon liable for selling faulty devices and failing ... at risk from side effects that include pain, bleeding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... September 16, 2014 Not all recovery ... take care to make sure all their patients are ... some, this may include the newly-introduced online therapy. Millennium ... which gives patients the opportunity to seek treatment from ... provide medical and clinical care at a distance. They ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3
... , ST. LOUIS, Aug. 24 Recent developments ... have attorney and clean water advocate Steve Tillery cautiously optimistic ... for the herbicide,s manufacturers. , , "Just ... York Times and the Peoria Journal Star have underscored the ...
... attack and stroke, but also prevent them. Scientists at Heidelberg ... for the first time on an animal model. Mice with ... in their vessels, but they are more stable. Thus, there ... circulation. The results of the study have been published in ...
... (BRONX, NY) - Concussions, whether from an accident, sporting ... higher level mental processes. Scientists have debated for centuries ... whether physiological changes that merely impair the way brain ... time, researchers at Albert Einstein College of Medicine of ...
... New Rochelle, NY, August 24, 2009Twitter, the increasingly popular ... convenient way to stay in touch with friends and ... real-time, on-the-go communication of healthcare information and medical alerts, ... Connectivity section of the latest issue of Telemedicine ...
... signals future heart risk, researcher says. , MONDAY, Aug. 24 ... women may also show if they have an increased risk ... found. , This finding is important because doctors might be ... to identify women who are at risk for developing heart ...
... , , CINCINNATI Aug. 24 The Kroger ... it easy and affordable for customers to take steps to keep ... , , This year, Kroger,s more than 1,900 ... at an affordable price. Beginning in September, flu vaccines will ...
Cached Medicine News:Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3Health News:Why 'thick' blood protects from a heart attack 2Health News:Strong link found between concussions and brain tissue injury 2Health News:Strong link found between concussions and brain tissue injury 3Health News:Twitter and health care -- can a tweet a day keep the doctor away? 2Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:Kroger's Family of Pharmacies Offer Customers Easy and Affordable Seasonal Flu Vaccinations 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducers with guidewires....
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
Medicine Products: